Prostate最新文献

{"title":"Transcriptome-Wide Association Study Identified Novel Blood Tissue Gene Biomarkers for Prostate Cancer Risk.","authors":"Yanfa Sun, Jingjing Zhu, Hua Zhong, Zichen Zhang, Fubo Wang, Akira Nakamura, Yanhui Liu, Jiawen Liu, Jie Yu, Guanghua Zeng, Xin Lin, Dan Zhou, Chong Wu, Liang Wang, Youping Deng, Lang Wu","doi":"10.1002/pros.24859","DOIUrl":"10.1002/pros.24859","url":null,"abstract":"<p><strong>Objective: </strong>A number of susceptibility genes in prostate tissue have been identified to be associated with prostate cancer (PCa) risk. However, the reported genes based on assessing prostate tissue could not fully explain PCa genetic susceptibility. It is believed that genes functioning in the immune system may fill in the gap of some missing heritability.</p><p><strong>Methods: </strong>To study potential susceptibility genes acting in such pathways, we performed a transcriptome-wide association study (TWAS) of 79,194 PCa cases and 61,112 control of European ancestry by using three sets of gene expression prediction models of blood tissue.</p><p><strong>Results: </strong>A total of 470 genes were associated at false discovery rates-corrected p-value < 0.05, of which 51 were implicated as likely causal genes based on fine-mapping analysis. Compared with previous literature, 133 novel genes were reported for the first time. Of the identified genes, five (CREB3L4, GSTP1, MAPK3, NKX3-1, and PIK3C2B) were enriched in a PCa signaling pathway, and 128 genes were enriched in five PCa categories. Importantly, 13 genes (SCP2, LMNA, ZNF148, H2AFV, TACC1, FLII, SUPT4H1, CD300LF, MYO9B, COX6B1, CTSA, EP300, and TSPO) showed consistent effect directions for the measured levels in circulating immune cells between PCa cases and controls, and 14 genes (SLC39A1, ZBTB7B, TRIM59, NCEH1, N4BP2, TAGAP, TACC1, TRAF1, AIP, SECTM1, C18orf54, ZNF793, YIF1B, and TSPO) showed consistency for levels in blood exosomes between PCa patients and controls.</p><p><strong>Conclusion: </strong>The identified blood-based candidate susceptibility genes provide further insights into the genetic basis of PCa risk.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"567-579"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reassessing the Role of Low PSA in Prognosis Across Grades of Prostate Cancer: A Cohort Study.","authors":"Cheng Shen, Zhan Chen, Fei-Hong Hu, Wei Wang, Yong-Shen Pan, Yong Zhang, Wei Zhang, Xin-Feng Chen, Hong-Lin Chen, Hua Zhu, Bing Zheng","doi":"10.1002/pros.24860","DOIUrl":"10.1002/pros.24860","url":null,"abstract":"<p><strong>Background: </strong>Prior studies have concentrated exclusively on how different prostate-specific antigen (PSA) levels affect the prognosis of high-grade prostate cancer (PCa), often overlooking the prognosis of low-grade PCa.</p><p><strong>Methods: </strong>The present cohort study included individuals diagnosed with PCa from the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2021. The all-cause mortality (ACM) and prostate cancer-specific mortality (PCSM) for each treatment group was calculated stratified by the four PSA levels (≤ 4.0, 4.1-10.0, 10.1-20.0, and > 20.0 ng/mL). Fine and Gray competing-risks analyses were conducted to calculate hazard ratios (HRs) with 95% confidence intervals (CIs). Cox proportional hazards regression analyses using PSA as a continuous variable with restricted cubic splines (RCS) were conducted to allow for potential nonlinear relationships.</p><p><strong>Results: </strong>This study encompassed 416,825 male patients diagnosed with PCa. Compared to individuals with PSA value between 4.1 and 10.0 ng/mL, a significant association between low levels of PSA (≤ 4.0 ng/mL) and an increased risk of ACM (AHR = 1.15, 95% CI: 1.12-1.19; p < 0.001) and PCSM (AHR = 1.49, 95% CI: 1.38-1.61; p < 0.001) was observed. Additionally, the increased risk of ACM (AHR = 1.35, 95% CI: 1.29-1.40; p < 0.001) and PCSM (AHR = 1.84, 95% CI: 1.67-2.02; p < 0.001) are more pronounced within the first 5 years post-diagnosis. In most subgroups, similar results were observed. The RCS curves further corroborated the correlation between PSA value and the risk of mortality.</p><p><strong>Conclusion: </strong>Low PSA levels are notably linked to a heightened risk for both ACM and PCSM, irrespective of the grade of PCa being high or low. There is a need to initiate new studies that tackle novel diagnostics and therapeutics.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"580-593"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RETRACTION: Interleukin-6 Protects LNCaP Cells From Apoptosis Induced by Androgen Deprivation Through the Stat3 Pathway.","authors":"","doi":"10.1002/pros.24873","DOIUrl":"10.1002/pros.24873","url":null,"abstract":"<p><strong>Retraction: </strong>S. O. Lee, W. Lou, C. S. Johnson, D. L. Trump, and A. C. Gao, \"Interleukin-6 Protects LNCaP Cells From Apoptosis Induced by Androgen Deprivation Through the Stat3 Pathway,\" The Prostate 60, no. 3 (2004): 178-186, https://doi.org/10.1002/pros.20045. The above article, published online on 02 February 2004 in Wiley Online Library (http://onlinelibrary.wiley.com/), has been retracted by agreement between the journal Editor-in-Chief, Dr. Samuel Denmeade; and Wiley Periodicals LLC. The publisher received a report from a third party which indicated that the portions of the actin band image had been duplicated between Figures 3A and 3B. The image duplication was confirmed by the publisher. The authors responded to an inquiry by the publisher but reported that the original data were no longer available and did not provide an explanation for the evidence of image duplications. The retraction has been agreed to because the evidence of image duplication, in which the same bands are used to illustrate different experimental results, fundamentally compromises the conclusions reported in the article. The authors did not respond to our notice regarding the retraction.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"627"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RETRACTION: Interleukin-4 Activates Androgen Receptor Through CBP/p300.","authors":"","doi":"10.1002/pros.24874","DOIUrl":"10.1002/pros.24874","url":null,"abstract":"<p><strong>Retraction: </strong>S. O. Lee, J. Y. Chun, N. Nadiminty, W. Lou, S. Feng, and A. C. Gao, \"Interleukin-4 Activates Androgen Receptor Through CBP/p300,\" The Prostate 69, no. 2 (2009): 126-132, https://doi.org/10.1002/pros.20865. The above article, published online on 25 September 2008 in Wiley Online Library (http://onlinelibrary.wiley.com/), has been retracted by agreement between the journal Editor-in-Chief, Dr. Samuel Denmeade; and Wiley Periodicals LLC. The publisher received a report from a third party which indicated that the Pol II bands had been duplicated between Figures 1A and 1B. This image duplication was confirmed by the publisher. The report also indicated that images had been reused between Figure 1 in this article and Figure 3 in the following article by some of the same authors: (Chun et al. 2006 [10.1158/1535-7163.MCT-05-0389]). Both articles describe different experimental conditions. The authors responded to an inquiry by the publisher but reported that the original data were no longer available and did not provide an explanation for the evidence of image duplications. The retraction has been agreed to because the evidence of image duplications both in this article and with other published research fundamentally compromises the results described in this article. The authors did not respond to our notice regarding the retraction.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"628"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11936716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched Cohort.","authors":"Tatsuya Shimomura, Fumihiko Urabe, Katsuki Muramoto, Takafumi Yanagisawa, Wataru Fukuokaya, Keiichiro Mori, Kojiro Tashiro, Kota Katsumi, Hidetsugu Takahashi, Kentaro Yoshihara, Keiichiro Miyajima, Yu Imai, Kosuke Iwatani, Sotaro Kayano, Taro Igarashi, Masaya Murakami, Shunsuke Tsuzuki, Hiroki Yamada, Jun Miki, Takahiro Kimura","doi":"10.1002/pros.24898","DOIUrl":"https://doi.org/10.1002/pros.24898","url":null,"abstract":"<p><strong>Introduction: </strong>The biology of castration-resistant prostate cancer (CRPC) status between conventional hormonal therapy and upfront androgen signaling inhibitor (ARSI) treatment might be different, and the biological status of prostate cancer after failure of sequential ARSI in conventional hormonal therapy would be the same as CRPC in upfront ARSI. In this study, we evaluate our proposed definition of CRPC in our cohort with propensity score-matched analysis.</p><p><strong>Patients and methods: </strong>A total of 885 patients diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC) who received conventional hormonal therapy, upfront androgen receptor signaling inhibitors (ARSI) with or without docetaxel therapy at Jikei University Hospital and its affiliated institutions, were included in this study. We compared survival outcomes between conventional hormonal therapy and upfront ARSI doublet treatment using conventional CRPC definition or our proposed CRPC definition.</p><p><strong>Result: </strong>CRPC-free survival (CRPCFS) and cancer-specific survival (CSS) is significantly better in upfront ARSI (upfront (+)) than upfront (-) group (median CRPCFS is 68 months vs. 18 months, median CSS is not reached (NR) and NR, (p < 0.0001 and p = 0.0381), respectively) in propensity score-matched cohort, although overall survival (OS) is not different. Median CSS and OS after conventional CRPC diagnosis is NR (upfront (-)) and 30 months (upfront (+)) (p = 0.0614), and 37 months (upfront (-)) and 24 months (upfront (+)) (p = 0.00503). OS is significantly better in upfront (-) than upfront (+) group with conventional CRPC definition. Median CSS and OS after our proposed CRPC diagnosis is 20 months (upfront (-)) and 30 months (upfront (+)) (p = 0.389), and 20 months (upfront (-)) and 24 months (upfront (+)) (p = 0.932).</p><p><strong>Conclusion: </strong>This proposed CRPC definition is thought to reflect the actual biological characteristics of prostate cancer with or without upfront ARSI treatment, and it is thought that the introduction of this definition should be considered when comparing the survival outcome between with or without upfront ARSI treatment.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?","authors":"Tatsuya Shimomura, Naoki Otsuka, Fumihiko Urabe, Katsuki Muramoto, Takafumi Yanagisawa, Wataru Fukuokaya, Keiichiro Mori, Kojiro Tashiro, Kota Katsumi, Hidetsugu Takahashi, Kentaro Yoshihara, Keiichiro Miyajima, Yu Imai, Kosuke Iwatani, Sotaro Kayano, Taro Igarashi, Masaya Murakami, Shunsuke Tsuzuki, Hiroki Yamada, Jun Miki, Takahiro Kimura","doi":"10.1002/pros.24885","DOIUrl":"https://doi.org/10.1002/pros.24885","url":null,"abstract":"<p><strong>Introduction: </strong>Prostate-specific antigen (PSA) kinetics serve as valuable surrogate markers for estimating survival outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen receptor pathway inhibitors (ARPI). While both the PSA response rate and absolute PSA value are typically assessed, determining which marker holds greater significance in real-world clinical settings is a critical clinical question. In this study, we compare the PSA response rate and absolute PSA value 3 months after the initiation of doublet ARPI therapy to identify which serves as a more effective surrogate marker in practice.</p><p><strong>Patients and methods: </strong>A total of 273 patients with mHSPC treated with ARPIs such as abiraterone acetate, enzalutamide, or apalutamide between February 2018 and June 2023 were included in this study. The study investigated PSA kinetics, including PSA levels at 3 months and the PSA response rate at 3 months. The outcome measures assessed were castration-resistant prostate cancer-free survival (CRPCFS), cancer-specific survival (CSS), and overall survival (OS).</p><p><strong>Results: </strong>The Youden index for the absolute PSA value at 3 months is 0.740 ng/mL. There is a significant difference in survival outcomes (CRPCFS, CSS, and OS) between patients with PSA levels > 0.740 ng/mL and those with ≤ 0.740 ng/mL. Additionally, the Youden index for the PSA response rate at 3 months is -99.80%. There is also a significant difference in survival outcomes (CRPCFS, CSS, and OS) between patients with response rates > -99.80% and those with rates ≤ -99.80%. In terms of clinical demographics with or without achieving PSA absolute value ≦ 0.740 ng/mL and PSA response rate ≦ -99.8%, although almost factors are different significantly (iPSA, age, PS, LN metastasis, EOD, CHAARTED criteria, LATTITUDE criteria, Hb, ALP, and LDH) between > 0.740 ng/mL and ≦ 0.740 ng/mL cohort, there are no significant difference in clinical factors other than age between > -99.80% and ≦ -99.80% cohort.</p><p><strong>Conclusion: </strong>Both the absolute value of PSA and the PSA response rate at 3 months after the initiation of ARPI can estimate survival outcomes. However, the PSA response rate is a more valuable surrogate marker for assessing treatment efficacy than the absolute PSA value. This is because the baseline clinical factors differ significantly among cohorts categorized by absolute PSA values, allowing for better predictions of survival outcomes at the start of treatment. Findings of this study could aid in decision-making following the initiation of doublet ARPI therapy within a short timeframe. Further studies are needed to validate our results.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE Study.","authors":"Takehiko Okamura, Kouji Izumi, Satoshi Kurokawa, Takashi Shima, Yuki Kato, Koji Mita, Manabu Kamiyama, Shogo Inoue, Seiji Hoshi, Nobumichi Tanaka, Yuko Yoshio, Hideki Enokida, Ippei Chikazawa, Noriyasu Kawai, Kohei Hashimoto, Takashi Fukagai, Kazuyoshi Shigehara, Shizuko Takahara, Atsushi Mizokami","doi":"10.1002/pros.24897","DOIUrl":"https://doi.org/10.1002/pros.24897","url":null,"abstract":"<p><strong>Background: </strong>Clinical trials rarely focus on elder patients with castration-resistant prostate cancer (CRPC), and data on the outcomes of second-generation androgen receptor signaling inhibitors (ARSIs) remain limited.</p><p><strong>Methods: </strong>The ENABLE study for prostate cancer was an investigator-initiated, multicenter, randomized controlled trial conducted in Japan to compare enzalutamide (ENZ) and abiraterone plus prednisolone (ABI). This sub-analysis was performed to evaluate the efficacy and the safety profiles between patients aged ≥ 75 (older) and < 75 years (younger), and then between the ENZ and ABI arms in the older and the younger cohort separately.</p><p><strong>Results: </strong>The ENZ arm included 41 younger and 51 older patients, while the ABI arm included 36 younger and 56 older patients. No significant differences in survival endpoints were observed between younger and older patients. Median time to prostate-specific antigen (PSA) progression (TTPP) was 15.2 months for younger and 21.2 months for older patients (HR 0.84, 95% CI 0.53-1.33, p = 0.4647). Median overall survival (OS) was 33.7 months for younger and 37.8 months for older patients (HR 0.80, 95% CI 0.50-1.29, p = 0.3651). Among older patients (n = 107), the ENZ arm had a TTPP of 21.2 months compared to 10.1 months for the ABI arm and an OS of 37.8 months compared to 44.7 months for the ABI arm (p = 0.1506 and p = 0.9321, respectively). Any grade and grade ≥ 3 adverse events were observed in 47 (61%) and 11 (14%) younger patients and 73 (68%) and 18 (17%) older patients, respectively. No significant differences were found in any grade or grade ≥ 3 adverse events between younger and older patients (p = 0.3487 and p = 0.6885, respectively).</p><p><strong>Conclusions: </strong>ARSIs demonstrated similar efficacy and safety in both younger and older patients. ENZ may be a more suitable option for older patients due to its higher PSA response rate.</p><p><strong>Clinical trial registration: </strong>This trial was registered with the University Hospital Medical Information Network (UMIN) Center under identifier UMIN000015529.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LHRH Antagonists Restore Serum Testosterone Faster Than LHRH Agonists in Prostate Cancer Patients After Radiotherapy.","authors":"Sangjon Pae, Shinichi Sakamoto, Xue Zhao, Takaaki Tamura, Tomohiko Kamasako, Akinori Takei, Yasutaka Yamada, Tomokazu Sazuka, Yusuke Imamura, Koichiro Akakura, Tomohiko Ichikawa","doi":"10.1002/pros.24899","DOIUrl":"https://doi.org/10.1002/pros.24899","url":null,"abstract":"<p><strong>Introduction: </strong>Maintaining a castration level of testosterone (TST) during radiation therapy combined with androgen deprivation therapy (ADT) is an essential strategy in the treatment of prostate cancer; however, hypogonadism can cause various complications. The aim was to compare serum TST recovery between LHRH agonists and LHRH antagonists.</p><p><strong>Methods: </strong>A total of 131 patients who underwent radiation therapy with ADT for prostate cancer were retrospectively analyzed. Serum TST levels after termination of ADT including LHRH agonists and antagonists were compared. Cox proportional hazards model and the Kaplan-Meier method were used for statistical analysis.</p><p><strong>Results: </strong>Median age, baseline TST, nadir TST, and duration of ADT were 71 years, 535 ng/dL, 10.92 ng/dL, and 12 months, respectively. Multivariate analysis identified significant associations of initial PSA ≥ 10.92 ng/mL (p = 0.0366), ADT ≥ 360 days (p = 0.0408), nadir TST ≤ 19 ng/dL (p = 0.0003), and LHRH agonist (p = 0.0027) with delayed TST recovery to castration level (50 ng/dL). We created a risk model based on these four independent risk factors (Low: 0-1 factor/Intermediate: 2 factors/High Risk: 3-4 factors). Each risk group significantly differentiated the TST recovery to castration level. Even after propensity score matching, recovery of TST to castration level and therapeutic level (200 ng/dL) was significantly delayed in the LHRH agonist group compared with the LHRH antagonist group (p = 0.0016, p = 0.0389, respectively).</p><p><strong>Conclusion: </strong>LHRH antagonists restored serum TST to castration and therapeutic levels faster than LHRH agonists in prostate cancer patients undergoing radiation therapy with ADT.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143774877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Dendritic Cells Injection After Radical Prostatectomy on Prostate Cancer in Mice.","authors":"Xiaoli Zhang, Weicong Sang, Xiaoping Hong, Haihong Qu, Jindong Tong, Qingtong Yi","doi":"10.1002/pros.24892","DOIUrl":"https://doi.org/10.1002/pros.24892","url":null,"abstract":"<p><strong>Background: </strong>To explore the therapeutic and preventive effect of dendritic cells injection combined with radical prostatectomy on prostate cancer in mice.</p><p><strong>Methods: </strong>We extracted antigens from mouse prostate cancer cells RM-1 and cocultured them with dendritic cells to induce maturation. We constructed in situ carcinoma and subcutaneous tumor models of the mouse prostate. The efficacy of dendritic cell injection combined with radical prostatectomy was evaluated in the carcinoma in situ model, and the ability of dendritic cells to prevent prostate cancer was evaluated in the subcutaneous tumor model. Means of assessment included ultrasonography, flow cytometry analysis, and Elisa.</p><p><strong>Results: </strong>Dendritic cell injection combined with radical prostatectomy effectively inhibited the growth of prostate carcinoma in situ in mice, as well as the growth of subcutaneous tumors of prostate cancer in mice. After dendritic cell injection, the levels of CD4 + T cells and Treg cells in the spleens of mice were significantly increased, and the levels of IL-2 and TNF-γ in the peripheral serum were significantly increased.</p><p><strong>Conclusions: </strong>Injection of mature dendritic cells induced by mouse prostate cancer cell RM-1 antigen can inhibit the growth of prostate cancer. Radical prostatectomy combined with dendritic cell injection might be a potential treatment strategy for prostate cancer.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid and Deep Prostate-Specific Antigen Decline is a Prognostic Marker in Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Multi-Intuitional Analysis.","authors":"Kotaro Suzuki, Takuto Hara, Hiromitsu Watanabe, Keita Nakane, Kiyoshi Takahara, Taku Naiki, Takahiro Yasui, Ryoichi Shiroki, Takuya Koie, Hideaki Miyake","doi":"10.1002/pros.24847","DOIUrl":"10.1002/pros.24847","url":null,"abstract":"<p><strong>Background: </strong>Prostate-specific antigen (PSA) kinetics has been investigated as a prognostic marker in post hoc analyses of clinical trials. This study validated the prognostic value of rapid and deep PSA decline in metastatic hormone-sensitive prostate cancer (mHSPC) using real-world data.</p><p><strong>Methods: </strong>In total, 1296 patients with mHSPC were retrospectively reviewed. We assessed the prognostic value of a PSA decline to ≤ 0.2 ng/mL after 12 weeks of treatment and investigated several potential risk factors for a poor PSA response.</p><p><strong>Results: </strong>Of 1296 patients, 714 (cohort 1: 55.1%) were treated with conventional hormonal therapy, while 582 (cohort 2: 44.9%) received androgen signaling inhibitors. There were significant differences in progression-free survival and overall survival between patients with PSA decline to ≤ 0.2 ng/mL by 12 weeks of treatment and others (p < 0.001 for each). In addition, patients with an initial PSA ≥ 200 ng/mL, Clinical T4 and Grade Group 5 were less likely to achieve PSA decline to ≤ 0.2 ng/mL by 12 weeks of treatment, with odds ratios of 0.31 (p < 0.001), 0.67 (p = 0.039) and 0.70 (p = 0.043), respectively.</p><p><strong>Conclusion: </strong>Our findings suggested that PSA decline to ≤ 0.2 ng/mL by 12 weeks of treatment may be a useful prognostic biomarker for mHSPC in the real-world setting. The prognostic value of this should be further investigated in a prospective cohort, and identification of an optimal cutoff value is necessary for its application in clinical trial design or clinical practice.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"448-455"},"PeriodicalIF":2.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142900324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}